Welcome to our dedicated page for Ambev SEC filings (Ticker: ABEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ambev S.A. (ABEV) SEC filings page brings together the company’s disclosures as a foreign private issuer with securities listed on the New York Stock Exchange. Ambev files an annual report on Form 20-F, as highlighted in multiple press releases announcing the availability of its annual reports for successive years. These 20-F filings contain the company’s complete audited financial statements, and the press releases note that American Depositary Receipt holders may request hard copies free of charge.
In addition to its annual reports, Ambev regularly furnishes Form 6-K current reports. The examples provided include notices to shareholders about ordinary shareholders’ meetings, extracts of minutes from Board of Directors meetings, and detailed explanations of decisions to distribute dividends and interest on capital based on extraordinary balance sheets. Other 6-Ks disclose policies on executive remuneration and the grant of stock options and restricted shares, as well as a policy on hiring services related or not related to auditing, which sets conditions for engaging independent auditors and lists non-authorized services to preserve auditor independence.
Ambev also uses Form 6-K to report related party transactions, such as its agreement with its controlling shareholder Anheuser-Busch InBev SA/NV for the use of the BEES B2B digital platform, and to provide consolidated and individual forms under Article 11 of CVM Instruction 358/2002 that detail management and related persons’ transactions in Ambev shares and ADRs. These forms show initial and final positions, deliveries of restricted shares, purchases, and sales.
On Stock Titan, these filings can be paired with AI-powered summaries that explain the key points of lengthy documents, highlight items such as dividend approvals, interest on capital distributions, insider share movements, and policy changes, and help readers navigate Ambev’s 20-F and 6-K disclosures more efficiently.
Ambev S.A. approved a small capital increase after beneficiaries exercised stock options under its 2026 stock option program, part of the Stock Option Plan first approved on July 30, 2013. The Board authorized the issuance of 2,026,133 new common shares with no par value.
The capital increase amounts to BRL 33,127,274.55, bringing total capital stock to BRL 58,308,213,544.96. The company reports potential dilution of 0.012855% based on the number of shares and 0.056846% relative to capital stock, indicating a very limited impact on existing shareholders.
Ambev S.A. outlined major shareholder matters, including how it plans to allocate net profit for 2025, management pay for 2026, bylaw changes, and a small capital increase from stock options. The proposals will be submitted at the April 30, 2026 digital shareholders’ meetings.
For 2025, Ambev reports net profits of R$ 15,503,399,889.90, with R$ 228,202,821.12 to the Tax Incentives Reserve, R$ 10,903,280,319.95 as interest on own capital, and R$ 6,854,843,618.36 to the Investments Reserve. The Board also proposes maximum 2026 compensation of up to R$ 162,176,731.00 for management and R$ 2,471,314.00 for the Fiscal Council.
The Board approved a capital increase from the Stock Option Plan, issuing 2,026,133 new common shares for R$ 33,127,274.55, raising capital stock from R$ 58,275,086,270.41 to R$ 58,308,213,544.96, now divided into 15,763,664,889 common shares with no par value.
AMBEV S.A. officer Malik Parente Guilherme reported an open-market sale of 20,971 common shares at a weighted average price of $2.76 per share on March 24, 2026. The shares were sold in multiple trades between $2.76 and $2.81. After this transaction, he directly holds 26,727 common shares.
AMBEV S.A. filed an initial insider ownership report for director Tadeu Almeida Cabral de Soares Ricardo. This Form 3 establishes his status as a board member and shows no reported purchases, sales, option exercises, gifts, or other insider stock transactions in this filing.
AMBEV S.A. officer Paulo Andre Zagman filed an initial Form 3 reporting his existing equity interests in the company. He holds common shares directly, including 332,071 common shares, along with several blocks of restricted shares that each represent a right to receive one common share minus withholding taxes.
The restricted shares relate to multiple incentive awards that vest on future dates, including December 1, 2026, March 1, 2027, December 1, 2027, December 14, 2027, February 28, 2028, and December 1, 2028. He also reports stock options over common shares at exercise prices such as 3.26, 3.91, 3.22, and 3.43 per share, with expirations between December 2026 and December 2029. The filing records his current holdings and does not show any new purchases or sales.
AMBEV S.A. executive Carla Smith de Vasconcellos Crippa Prado filed an initial Form 3 reporting her equity holdings. She directly owns 130,203 common shares and multiple tranches of restricted shares that each represent rights to receive one common share, scheduled to vest between December 2026 and December 2028. She also holds several stock option grants on common shares, with exercise prices ranging from about $3.11 to $3.91 per share and expiration dates from late 2026 through 2029, showing a mix of current ownership and longer-term incentive awards.
AMBEV S.A. officer Eduardo Braga Cavalcanti de Lacerda filed an initial ownership report listing his equity interests in the company. The filing shows multiple grants of restricted shares, each representing a contingent right to receive one common share, generally at no exercise price and subject to withholding taxes.
These restricted shares vest on various dates, including December 1, 2026, March 1, 2027, December 2, 2027, February 28, 2028, December 1, 2028, and December 18, 2028. He also holds several stock option awards over common shares with exercise prices between $3.22 and $3.91 per share, expiring between 2026 and 2029, as well as directly held common shares. The report records existing holdings rather than new market transactions.
AMBEV S.A. officer Duarte Valdecir filed an initial ownership report showing direct holdings of 705,363 common shares. The filing also lists multiple grants of restricted shares, each representing a right to receive one common share minus withholding taxes, vesting on dates from December 1, 2026 through December 1, 2028.
In addition, he holds several stock option awards over common shares with exercise prices such as 3.26, 3.91, 3.22 and 3.43 per share, expiring between December 2, 2026 and December 3, 2029. The entry is a Form 3, so it records existing positions rather than new market purchases or sales.
AMBEV S.A. director Carlos De Marchi Victorio filed an initial Form 3 reporting his equity interests in the company. He reports direct ownership of 1,477,693 common shares and indirect ownership of 25,653,369 common shares through DM Investimentos S.A., where he is the financial beneficial owner.
He also reports multiple grants of restricted shares that each represent a right to receive one common share minus withholding taxes, with vesting dates running from December 1, 2026 through December 1, 2030. In addition, he holds several stock option awards over hundreds of thousands of common shares with exercise prices between 3.22 and 3.91 and expirations from 2026 to 2029.
AMBEV S.A. director Lia Machado de Matos filed an initial ownership report showing several awards of restricted shares tied to Ambev common stock. The positions include blocks of restricted shares corresponding to 26,312 and 28,641 underlying common shares held directly, among other tranches.
Footnotes explain that each restricted share represents a contingent right to receive one common share minus withholding taxes, with vesting dates on December 1, 2026, December 1, 2027, December 1, 2028, December 2, 2029, and December 1, 2030. The filing reports these holdings and does not disclose any open-market purchases or sales.